Historical Context & Motivation
The relationship between lung disease and heart failure has been recognized for centuries, though the precise pathophysiological mechanisms were not elucidated until the twentieth century. The term cor pulmonale — literally pulmonary heart — describes structural and functional changes in the right ventricle that arise secondary to diseases affecting the pulmonary vasculature or the lung parenchyma. Unlike left-sided heart failure, which typically originates from systemic hypertension or coronary artery disease, cor pulmonale reflects a fundamentally different hemodynamic burden: the right ventricle must pump against an abnormally elevated pulmonary vascular resistance. Understanding this entity is critical for healthcare professionals because it represents one of the most common cardiac consequences of chronic respiratory disease and carries significant morbidity and mortality.
With chronic obstructive pulmonary disease (COPD) affecting over 380 million people worldwide and interstitial lung diseases growing in prevalence, the clinical question that drives this lesson remains urgent: How do chronic pulmonary conditions impose a hemodynamic burden on the right ventricle, and at what point does compensatory adaptation give way to overt heart failure?
Core Principles & Definitions
To understand cor pulmonale, one must appreciate the fundamental differences between the right and left ventricles and the circulatory beds they serve. The right ventricle (RV) is a thin-walled, crescent-shaped chamber that normally operates as a volume pump in a low-pressure, low-resistance pulmonary circuit. Mean pulmonary artery pressure (mPAP) at rest is approximately 14 mmHg, compared to a mean systemic arterial pressure of roughly 93 mmHg. This enormous difference reflects the fact that the pulmonary vasculature is a highly compliant, low-resistance system. When this resistance rises chronically — whether from hypoxic vasoconstriction, vascular remodeling, or parenchymal destruction — the right ventricle must generate greater wall tension, initiating a cascade of hypertrophy, dilation, and eventual failure.
Pulmonary Hypertension (PH)
Right Ventricular Hypertrophy (RVH)
Hypoxic Pulmonary Vasoconstriction (HPV)
Pulmonary Vascular Remodeling
Right Heart Failure
Visual Explanation — Pathophysiology of Cor Pulmonale
The diagram above illustrates why cor pulmonale is fundamentally a disease of the pulmonary vasculature acting upon the right heart. The initiating event is always a process that reduces the cross-sectional area of the pulmonary vascular bed or actively constricts pulmonary arterioles. In COPD, emphysematous destruction of alveolar walls obliterates the capillary network, while chronic hypoxia triggers sustained HPV. In interstitial lung disease (ILD), fibrotic tissue replaces normal parenchyma and compresses or obliterates pulmonary capillaries. In chronic thromboembolic disease, organized clot physically obstructs the pulmonary arterial lumen. Despite differing etiologies, each condition converges on the same hemodynamic result: elevated pulmonary vascular resistance and increased right ventricular afterload.
Hemodynamic Framework & Key Relationships
Although cor pulmonale is diagnosed clinically and echocardiographically rather than through mathematical calculation, the hemodynamic principles governing pulmonary pressure and right ventricular performance can be expressed quantitatively. Understanding these relationships clarifies why even modest increases in pulmonary vascular resistance produce disproportionate effects on the right ventricle.
Classification & Etiologies of Cor Pulmonale
Cor pulmonale can be classified by temporal course — acute versus chronic — and by the site of pathology within the respiratory system. Acute cor pulmonale develops over hours to days, most commonly from massive pulmonary embolism, which suddenly obstructs a large portion of the pulmonary vascular bed and causes acute RV pressure overload and dilation. Chronic cor pulmonale develops over months to years as progressive pulmonary vascular disease or parenchymal destruction slowly raises PVR. The chronic form allows time for compensatory RV hypertrophy, which may maintain cardiac output for a prolonged period before decompensation occurs.
Among the chronic etiologies, COPD accounts for approximately 80–90% of all cases of cor pulmonale in clinical practice, making it by far the most common cause. The pathophysiology in COPD is multifactorial: emphysematous capillary bed destruction reduces vascular cross-sectional area, chronic alveolar hypoxia drives sustained HPV, hypercapnia and respiratory acidosis augment vasoconstriction, and secondary polycythemia increases blood viscosity. These overlapping mechanisms explain why patients with severe COPD (GOLD stage III–IV) are at particularly high risk. Importantly, the presence of cor pulmonale in COPD is associated with a markedly worse prognosis — five-year survival drops from approximately 70% to less than 30% once signs of right heart failure become apparent.
Worked Example — Interpreting Hemodynamics in Cor Pulmonale
Consider the following clinical scenario: A 68-year-old man with GOLD stage IV COPD presents with worsening dyspnea, peripheral edema, and an elevated JVP. Right heart catheterization reveals the following: cardiac output (CO) = 4.0 L/min, mean pulmonary artery pressure (mPAP) = 38 mmHg, pulmonary capillary wedge pressure (PCWP) = 10 mmHg. We will calculate PVR and interpret the findings.
Right vs. Left Heart Failure — Key Distinctions
One of the most clinically important skills is distinguishing cor pulmonale (right heart failure from pulmonary causes) from left-sided heart failure. While both conditions may present with dyspnea, the underlying pathophysiology, physical examination findings, and treatment strategies differ fundamentally. Clinicians must also recognize that left heart failure can secondarily cause pulmonary hypertension (postcapillary PH), but this is explicitly excluded from the definition of cor pulmonale.
| Feature | Cor Pulmonale (Right Heart Failure) | Left Heart Failure |
|---|---|---|
| Primary Etiology | Lung disease, pulmonary vascular disease, chest wall disorders | Coronary artery disease, systemic hypertension, valvular heart disease |
| Hemodynamic Pattern | Precapillary PH: ↑ mPAP, normal PCWP (≤ 15 mmHg), ↑ PVR | Postcapillary PH: ↑ mPAP, ↑ PCWP (> 15 mmHg), normal or mildly ↑ PVR |
| Venous Congestion | Systemic: ↑ JVP, hepatomegaly, peripheral edema, ascites | Pulmonary: dyspnea, orthopnea, crackles, pulmonary edema |
| Cardiac Exam | RV heave, loud P2, tricuspid regurgitation murmur | Displaced apical impulse, S3 gallop, mitral regurgitation murmur |
| ECG Findings | Right axis deviation, P pulmonale, RV hypertrophy pattern, right bundle branch block | Left axis deviation, LV hypertrophy, Q waves (if ischemic), left bundle branch block |
| Treatment Focus | Treat underlying lung disease, supplemental O₂, diuretics, pulmonary vasodilators (selected cases) | ACE inhibitors/ARBs, beta-blockers, diuretics, aldosterone antagonists, revascularization |
Connection to Advanced Pulmonary Hypertension Classification
Cor pulmonale exists within the broader framework of pulmonary hypertension (PH) classification. The current WHO/ESC classification system divides PH into five groups based on etiology and mechanism. Cor pulmonale most directly corresponds to Group 3: PH due to lung diseases and/or hypoxia, though the term can also apply to Group 4 (chronic thromboembolic PH) and certain Group 5 conditions. Understanding this classification framework is essential for advanced study, as it dictates therapeutic strategy and prognosis. For instance, pulmonary vasodilator therapies (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues) that are mainstays in Group 1 pulmonary arterial hypertension (PAH) have shown limited efficacy — and potential harm — in Group 3 PH due to worsening ventilation-perfusion mismatch.
| Feature | Cor Pulmonale (This Lesson) | Advanced PH Classification |
|---|---|---|
| Scope | Focuses on RV consequences of chronic lung disease | Encompasses 5 groups with diverse etiologies including idiopathic PAH, connective tissue diseases, portal hypertension |
| Diagnostic Approach | Clinical signs + echocardiography + underlying lung disease | Right heart catheterization required; vasoreactivity testing for Group 1; CTPA for Group 4; extensive workup to exclude all groups |
| Treatment | Treat underlying lung disease, O₂ therapy, diuretics | Group-specific targeted therapies (prostacyclins, ERAs, PDE-5i), surgical options (pulmonary thromboendarterectomy for Group 4), transplantation |
| Molecular Mechanisms | HPV, vascular remodeling from chronic hypoxia, capillary bed loss | Endothelin overexpression, NO/prostacyclin deficiency, BMPR2 mutations, in situ thrombosis, angioproliferative plexiform lesions |
As you advance in your studies, you will explore how molecular signaling pathways — including the nitric oxide–cyclic GMP pathway, the endothelin system, and prostacyclin signaling — contribute to the vascular remodeling that underlies pulmonary hypertension in all its forms. These molecular targets underpin the pharmacotherapy used in Group 1 PAH and represent active areas of translational research for Group 3 PH and cor pulmonale.
Practice Problems
Lesson Summary
Cor pulmonale is defined as right ventricular hypertrophy and/or dilation resulting from diseases of the pulmonary vasculature, lung parenchyma, or chest wall — explicitly excluding left heart disease as the cause. The central hemodynamic mechanism is elevated pulmonary vascular resistance (PVR), driven by hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, capillary bed destruction, and secondary polycythemia. These processes elevate mean pulmonary artery pressure (mPAP) above 20 mmHg, imposing chronic pressure overload on the thin-walled right ventricle.
The right ventricle initially compensates through concentric hypertrophy, which normalizes wall stress (Laplace relationship), but progressive afterload eventually overwhelms compensatory mechanisms, producing RV dilation and failure — manifesting as elevated JVP, peripheral edema, hepatomegaly, and reduced cardiac output. COPD is the most common cause (80–90% of cases), with other etiologies including interstitial lung disease, chronic thromboembolic disease, and severe obesity hypoventilation syndrome. The diagnostic hallmark is precapillary pulmonary hypertension (elevated mPAP with normal PCWP ≤ 15 mmHg), and management centers on treating the underlying pulmonary condition, correcting hypoxia with supplemental oxygen, and managing volume overload with diuretics.